CCRM
Swarali Joshi is an experienced operations associate with a strong background in biotechnology and project management. Currently serving as Operations Associate II at CCRM since April 2022, Swarali has successfully completed multiple cell therapy projects while ensuring compliance with health regulations and quality standards. Previous experience includes roles such as Clinical Research Assistant at IRCM, where Swarali managed biobank sample handling and analyzed immunological data. At Paragon Consulting, Swarali provided pro bono consultancy in marketing and strategy to non-profit organizations. Additionally, Swarali has conducted research on COVID-19 biomarkers during an internship at RI-MUHC and contributed to academic instruction as a Teaching Assistant at McGill University. Swarali holds a Master's degree in Applied Science from McGill University and a Bachelor's degree in Biotechnology from DY Patil University.
CCRM
1 followers
Regenerative Medicine (RM), which aims to harness the power of stem cells, biomaterials and molecules to repair, regenerate or replace diseased cells, tissues and organs, has the promise to treat, manage and perhaps cure some of the most devastating and costly diseases in the world today. Many new and potentially life-changing RM-based treatments never reach patients because they are not successfully moved from the laboratory to a stage where they can be used in medicine. In order to fulfill RM’s promise to treat the many diseases affecting our population, a world-renowned group of stem cell scientists and engineers have come together to form CCRM, a leader in developing and commercializing regenerative medicine and cell therapy technologies. CCRM formally launched on June 14, 2011. CCRM supports the development and commercialization of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy.